Want to see AU:HCT full AI Analyst Report?
Top Page
Holista Colltech Limited
(Sydney:HCT)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.08
▼(-13.33% Downside)
Action:Reiterated
Date:05/08/26
The score is held down primarily by weak financial performance—revenue contraction, deeper losses, and persistent negative operating/free cash flow—along with elevated leverage despite equity turning positive. Technicals are only mildly supportive in the near term, while valuation remains unattractive/unclear due to negative earnings and no dividend yield provided.
Positive Factors
Diversified revenue model
Multiple monetization channels — direct-to-consumer product sales, B2B ingredient supply, contract manufacturing and licensing — reduce single-channel concentration risk. This structural diversity supports more stable long-term revenue opportunities and multiple paths to scale as each channel can be expanded independently.
Negative Factors
Sharp revenue contraction
A severe decline in reported revenue signals fundamental demand weakness or lost customer contracts and undermines scale economics. Persistently lower top-line reduces ability to cover fixed costs, compromises margin recoveries, and makes profitable growth and investment more difficult without a clear revenue turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue model
Multiple monetization channels — direct-to-consumer product sales, B2B ingredient supply, contract manufacturing and licensing — reduce single-channel concentration risk. This structural diversity supports more stable long-term revenue opportunities and multiple paths to scale as each channel can be expanded independently.
Read all positive factors
Holista Colltech Limited (HCT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$29.43M
Dividend YieldN/A
Average Volume (3M)72.05K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue Growth2.96%
EPS Growth-866.67%
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding367,834,350
10 Day Avg. Volume123,924
30 Day Avg. Volume72,050
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)28.04
Price to Sales (P/S)5.45
P/FCF Ratio-20.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Holista Colltech Limited Business Overview & Revenue Model
Company Description
Holista CollTech Limited is a biotechnology firm with operations spanning Australia, Malaysia, and the United States. Its business activities are organized into four key divisions: Supplements, Ovine Collagen, Infection Control Solutions, and Food...
How the Company Makes Money
HCT makes money primarily by commercializing its health and wellness offerings through the sale of products and/or ingredients to customers (for example, consumers, distributors, or business customers depending on the channel). Revenue is generate...
Holista Colltech Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.76M | 5.60M | 5.95M | 8.24M | 8.02M |
| Gross Profit | 770.25K | 87.03K | 370.06K | 4.24M | 1.31M |
| EBITDA | -788.46K | 304.37K | -4.52M | -1.02M | -957.40K |
| Net Income | -948.92K | -84.21K | -4.81M | -1.45M | -1.26M |
Balance Sheet | |||||
| Total Assets | 5.87M | 3.34M | 3.35M | 5.52M | 6.93M |
| Cash, Cash Equivalents and Short-Term Investments | 2.16M | 21.72K | 59.77K | 117.53K | 1.21M |
| Total Debt | 1.59M | 1.77M | 1.57M | 1.22M | 890.32K |
| Total Liabilities | 6.29M | 6.71M | 6.74M | 3.96M | 3.95M |
| Stockholders Equity | 1.12M | -1.73M | -1.97M | 2.83M | 4.10M |
Cash Flow | |||||
| Free Cash Flow | -1.52M | -1.02M | -411.67K | -1.19M | -1.72M |
| Operating Cash Flow | -1.35M | -1.01M | -407.12K | -1.11M | -1.68M |
| Investing Cash Flow | -176.36K | 692.12K | -46.70K | -105.69K | 50.35K |
| Financing Cash Flow | 3.65M | 143.75K | 418.42K | 120.85K | 109.49K |
Holista Colltech Limited Technical Analysis
Positive
0.09
Price Trends
0.07
Positive
0.07
Positive
0.08
Positive
Market Momentum
<0.01
Negative
64.68
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HCT, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.08, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 64.68 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:HCT.
Holista Colltech Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | AU$222.23M | 23.09 | 56.29% | ― | 174.51% | 265.77% | |
78 Outperform | AU$131.09M | 15.23 | 12.22% | 2.19% | 27.60% | 96.31% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | AU$71.53M | 19.05 | 8.70% | ― | 23.29% | ― | |
45 Neutral | AU$27.71M | -0.30 | 19.78% | ― | 6.22% | 39.68% | |
44 Neutral | AU$29.43M | -30.77 | -321.20% | ― | 2.96% | -866.67% | |
44 Neutral | AU$7.33M | -0.01 | 226.76% | ― | -32.83% | 83.37% |
* Consumer Defensive Sector Average
AU:HCT
Holista Colltech Limited
0.08
<0.01
14.29%
AU:NOU
Noumi Limited
0.10
-0.04
-28.57%
AU:BLS
Bioxyne Limited
0.95
0.49
110.00%
AU:BUB
Bubs Australia Ltd.
0.08
-0.10
-55.56%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
0.00
0.00%
AU:CLV
Clover Corporation Limited
0.85
0.33
63.13%
Holista Colltech Limited Corporate Events
Holista Colltech Plans New Share Placement on ASX
Jul 9, 2026
Holista Colltech Limited has notified the ASX of a proposed issue of up to 5,296,055 ordinary fully paid shares, to be undertaken as a placement or other type of equity issue. The securities are intended to be quoted on the ASX, with the company c...
Holista Colltech Secures Convertible Loan to Settle ProImmune Liability
Jul 9, 2026
Holista Colltech Limited, a Perth-based health and wellness company listed on the ASX, develops and markets dietary supplements, low-GI food ingredients, ovine collagen products, and natural sanitizers for consumer and industrial use. Its business...
Holista JV Buys Collie Industrial Site for New Collagen Plant
Jun 18, 2026
Holista Colltech’s joint venture Ovicoll Pty Ltd has acquired a 3,974-square-metre industrial block in Collie, Western Australia, for $231,000 to house a new sheep collagen and nano-collagen production facility. The land purchase follows the...
Holista clarifies JV terms and guarantee for Collie collagen plant
Jun 17, 2026
Holista Colltech has clarified details of its binding joint venture with Hong Kong–listed Swang Chai Chuan to fund, develop and operate an ovine nano-collagen production facility in Collie, Western Australia, including the status of related ...
Holista Colltech shareholders back all resolutions at 2026 AGM
May 25, 2026
Holista Colltech Limited reported that all resolutions put to shareholders at its 25 May 2026 Annual General Meeting were passed by poll. Investors overwhelmingly backed the remuneration report, the elections of directors Robert Gemelli and Sam Ye...
Holista Colltech Signals Governance-Led Turnaround at 2026 AGM
May 25, 2026
Holista Colltech Limited outlined a broad transformation program at its 2026 annual general meeting, highlighting a refreshed board, stronger governance and the substantial resolution of major legacy legal matters. The company reported a stabilise...
Holista seals joint venture to build WA ovine nano-collagen plant
May 4, 2026
Holista Colltech Limited has entered a binding 50:50 joint venture with Hong Kong–listed Swang Chai Chuan Limited to fund, develop, and operate an ovine nano-collagen production facility in Collie, Western Australia, via Ovicoll Pty Ltd. SCC...
Holista Colltech holds revenue steady but posts cash outflow in March quarter
Apr 28, 2026
Holista Colltech reported quarterly revenue of about $1.49 million for the period ended 31 March 2026, with approximately $1.47 million contributed by its core supplements segment, underscoring resilient customer demand. Smaller contributions came...
Holista Colltech Sets 2026 AGM and Urges Timely Proxy Voting
Apr 24, 2026
Holista Colltech Limited has scheduled its Annual General Meeting for 2:00 p.m. AWST on Monday, 25 May 2026, to be held at Stantons International, 40 Kings Park Road, West Perth, Western Australia. Shareholders are encouraged to participate either...
Holista Colltech Sets 2026 AGM to Confirm Directors and Expand Capital-Raising Capacity
Apr 24, 2026
Holista Colltech Limited has called its annual general meeting for 25 May 2026 in West Perth, where shareholders will review the company’s financial statements for the year ended 31 December 2025 and vote on the non-binding adoption of the r...
Holista Colltech Trading Reinstated on ASX After Legal Matter Update
Apr 22, 2026
Trading in Holista Colltech Limited shares on the ASX has been reinstated following the company’s release of an announcement about its legal matter with ProImmune Company LLC. The lifting of the suspension restores liquidity for shareholders...
Holista Colltech Strikes Discounted Settlement After US$2.06m ProImmune Judgment
Apr 22, 2026
Holista Colltech has been ordered by the Supreme Court of Western Australia to satisfy a US$2.06 million US judgment obtained by The ProImmune Company over alleged breaches of minimum performance obligations under distribution agreements for Immun...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.